Reporters learned from multiple sources that the weight loss indication of Masdu peptide injection, the first domestically produced GLP-1 weight loss innovative drug developed by Innovent Biologics, is expected to be approved as early as this week. As of the close of June 26, Innovent Biologics' stock price fell by about 5%. Innovent Biologics previously publicly stated that both weight loss and glucose-lowering indications of Masdu peptide are expected to be approved this year. Masdu peptide is the world's first GCG/GLP-1 dual receptor agonist weight loss drug. After approval, it is expected to break the current global weight loss drug competition dominated by multinational giants Novo Nordisk and Eli Lilly, and is expected to improve the accessibility of GLP-1 weight loss drugs.